Michael A. Metzger - 27 Sep 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President and COO, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
27 Sep 2021
Net transactions value
-$300,885
Form type
4
Filing time
28 Sep 2021, 16:36:29 UTC
Previous filing
22 Sep 2021
Next filing
27 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $175,946 +24,437 +138% $7.20 42,096 27 Sep 2021 Direct
transaction SNDX Common Stock Sale $476,832 -24,437 -58% $19.51 17,659 27 Sep 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24,437 -100% $0.000000* 0 27 Sep 2021 Common Stock 24,437 $7.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The sales price ranged from $19.02 to $19.96
F3 This option is fully vested.